iA Global Asset Management Inc. Sells 85,772 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

iA Global Asset Management Inc. lessened its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 19.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 355,119 shares of the company’s stock after selling 85,772 shares during the quarter. iA Global Asset Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $7,827,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Smithfield Trust Co raised its stake in Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after purchasing an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Teva Pharmaceutical Industries in the third quarter valued at about $50,000. Ameliora Wealth Management Ltd. acquired a new position in Teva Pharmaceutical Industries in the fourth quarter valued at about $66,000. IFP Advisors Inc raised its stake in Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock valued at $88,000 after purchasing an additional 1,960 shares in the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in Teva Pharmaceutical Industries in the fourth quarter valued at about $104,000. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $16.27 on Friday. The business has a 50 day moving average of $17.88 and a 200-day moving average of $18.23. Teva Pharmaceutical Industries Limited has a 1 year low of $12.51 and a 1 year high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The company has a market capitalization of $18.44 billion, a P/E ratio of -11.22, a P/E/G ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, equities research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently commented on TEVA. StockNews.com raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Wednesday. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Barclays lowered their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. Bank of America lowered their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Finally, UBS Group lowered their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.